TandemAI
TandemAI provides an integrated drug discovery platform combining AI and physics-based tools, aimed at democratizing access to advanced drug discovery technologies. The company recently raised $35 million in Series A financing to enhance its computational and experimental capabilities.
Services
TandemAI offers Discovery as a Service, providing an integrated platform for drug discovery. Their services encompass both computational and experimental approaches, making advanced tools accessible to researchers and scientists. They focus on democratizing access to cutting-edge AI and physics-based drug discovery tools with a user-friendly interface. Additionally, their services include the TandemViz™ 1.0, a web-based graphical user interface that integrates computational analyses with experimental data seamlessly.
Products
TandemAI provides an array of products designed to enhance drug discovery processes. At the core of their offerings is the TandemViz™ 1.0, a web-based graphical user interface for seamless integration of computational and experimental data. The platform leverages physics-based molecular simulation to study drug interactions and bindings with protein atoms. Moreover, their in-house supercomputing infrastructure is optimized for drug discovery workflows, supporting complex computations and data models.
Funding
TandemAI has successfully raised $35 million in Series A financing. This capital is aimed at expanding their integrated computational and wet lab solutions. The funding enables the acceleration of drug discovery processes, providing the resources necessary to enhance their platform and integrate additional advanced tools.
Sector
TandemAI operates within the pharmaceutical and biotechnology sector, specifically focusing on drug discovery. They integrate advanced technologies such as artificial intelligence and physics-based molecular simulations to improve the efficiency and accuracy of pre-clinical drug candidate development. Their goal is to enhance the success rate of pre-clinical drug candidates, contributing to more effective and faster drug discovery processes.
Collaborations
TandemAI collaborates with the global scientific community to enhance the success rates of pre-clinical drug candidates. These partnerships help in improving the drug discovery process by incorporating global expertise and innovative techniques. Through these collaborations, TandemAI aims to bring advanced drug discovery tools to a broader audience, fostering a more inclusive scientific environment.